Сравнение

Nafarelin vs. Pasireotid

Два пептида рядом — идентичность, доказательная база, правовой статус и известные нежелательные явления.

Идентичность

Категория

Исследования (прочее)

Номер CAS

нет данных

396091-73-9

Молекулярная масса

нет данных

1047.21 g/mol

Период полувыведения

нет данных

Последовательность

нет данных

Механизм действия

Nafarelin

Nafarelin is a potent GnRH agonist: after an initial stimulation ('flare'), continuous receptor occupancy leads to downregulation and thereby suppression of LH, FSH and the downstream sex hormones.

Pasireotid

Pasireotide binds more broadly than older somatostatin analogs (SSTR1/2/3/5) with particularly high affinity for SSTR5. This suppresses, among others, ACTH release in Cushing's disease and GH release in acromegaly.

Доказательная база

Наивысшая доказательность

РКИ на людях

Исследования

из них на людях

Зафиксированные эффекты

Открытые противоречия

Задокументированные нежелательные явления

Правовой статус

Country	Nafarelin	Pasireotid
Германия	Рецептурный	Рецептурный
США	Рецептурный	Рецептурный

Полные записи

Frequently asked questions

What is the difference between Nafarelin and Pasireotid?: Nafarelin is classified as "Исследования (прочее)", while Pasireotid is classified as "Исследования (прочее)". Nafarelin: Nafarelin is a GnRH agonist and the only member of this class delivered as a nasal spray. It is approved for treating endometriosis and central precocious puberty. Pasireotid: Pasireotide is a multireceptor somatostatin analog binding to four of the five somatostatin receptors (especially SSTR5). It is approved for Cushing's disease and acromegaly. This page contrasts both neutrally and source-based — with no usage or dosing recommendation.
Which peptide is better supported by science, Nafarelin or Pasireotid?: The highest available evidence level is "РКИ на людях" for Nafarelin and "РКИ на людях" for Pasireotid. A higher evidence level means more robust data, but says nothing about suitability for an individual. The full body of evidence is on each peptide's own page.
What is the legal status of Nafarelin and Pasireotid in Germany and the United States?: Германия: Nafarelin — Рецептурный, Pasireotid — Рецептурный. США: Nafarelin — Рецептурный, Pasireotid — Рецептурный. These are factual summaries with source and review date on the individual pages.

Country

Nafarelin

Pasireotid

Германия

Рецептурный

США

Рецептурный

Frequently asked questions

What is the difference between Nafarelin and Pasireotid?

Nafarelin is classified as "Исследования (прочее)", while Pasireotid is classified as "Исследования (прочее)". Nafarelin: Nafarelin is a GnRH agonist and the only member of this class delivered as a nasal spray. It is approved for treating endometriosis and central precocious puberty. Pasireotid: Pasireotide is a multireceptor somatostatin analog binding to four of the five somatostatin receptors (especially SSTR5). It is approved for Cushing's disease and acromegaly. This page contrasts both neutrally and source-based — with no usage or dosing recommendation.

Which peptide is better supported by science, Nafarelin or Pasireotid?

The highest available evidence level is "РКИ на людях" for Nafarelin and "РКИ на людях" for Pasireotid. A higher evidence level means more robust data, but says nothing about suitability for an individual. The full body of evidence is on each peptide's own page.

What is the legal status of Nafarelin and Pasireotid in Germany and the United States?

Германия: Nafarelin — Рецептурный, Pasireotid — Рецептурный. США: Nafarelin — Рецептурный, Pasireotid — Рецептурный. These are factual summaries with source and review date on the individual pages.